Systemic Infusion of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Peritoneal Dialysis Patients: Feasibility and Safety

Overview

Journal Cell J

Specialty Cell Biology

Date 2018 Aug 21

PMID 30123994

Citations 18

Authors

Sudabeh Alatab

Soroosh Shekarchian

Iraj Najafi

Reza Moghadasali

Naser Ahmadbeigi

Mohammad Reza Pourmand

Tina Bolurieh

Neda Jaroughi

Gholamreza Pourmand

Nasser Aghdami

Affiliations

Soon will be listed here.

Abstract

Objective: Using mesenchymal stem cells (MSCs) is regarded as a new therapeutic approach for improving fibrotic diseases. the aim of this study to evaluate the feasibility and safety of systemic infusion of autologous adipose tissue-derived MSCs (AD-MSCs) in peritoneal dialysis (PD) patients with expected peritoneal fibrosis.

Materials And Methods: This study was a prospective, open-label, non-randomized, placebo-free, phase I clinical trial. Case group consisted of nine eligible renal failure patients with more than two years of history of being on PD. Autologous AD-MSCs were obtained through lipoaspiration and expanded under good manufacturing practice conditions. Patients received 1.2 ± 0.1×106 cell/kg of AD-MSCs via cubital vein and then were followed for six months at time points of baseline, and then 3 weeks, 6 weeks, 12 weeks, 16 weeks and 24 weeks after infusion. Clinical, biochemical and peritoneal equilibration test (PET) were performed to assess the safety and probable change in peritoneal solute transport parameters.

Results: No serious adverse events and no catheter-related complications were found in the participants. 14 minor reported adverse events were self-limited or subsided after supportive treatment. One patient developed an episode of peritonitis and another patient experienced exit site infection, which did not appear to be related to the procedure. A significant decrease in the rate of solute transport across peritoneal membrane was detected by PET (D/P cr=0.77 vs. 0.73, P=0.02).

Conclusion: This study, for the first time, showed the feasibility and safety of AD-MSCs in PD patients and the potentials for positive changes in solute transport. Further studies with larger samples, longer follow-up, and randomized blind control groups to elucidate the most effective route, frequency and dose of MSCs administration, are necessary (Registration Number: IRCT2015052415841N2).

Citing Articles

Long-term effects of infrapatellar fat pad SVF infiltration in knee osteoarthritis management: A prospective cohort study.

Labarre K, Zimmermann G Bone Rep. 2025; 24:101827.

PMID: 39911147 PMC: 11795827. DOI: 10.1016/j.bonr.2025.101827.

MSC-exosomes pretreated by Danshensu extracts pretreating to target the hsa-miR-27a-5p and STAT3-SHANK2 to enhanced antifibrotic therapy.

Liang J, Zhao J, Yang L, Wang Q, Liao J, Li J Stem Cell Res Ther. 2025; 16(1):40.

PMID: 39901236 PMC: 11792327. DOI: 10.1186/s13287-025-04181-0.

Biodegradable exosome-engineered hydrogels for the prevention of peritoneal adhesions via anti-oxidation and anti-inflammation.

Wang W, Ren Y, Yu Q, Jiang L, Yu C, Yue Z Mater Today Bio. 2024; 29:101312.

PMID: 39525394 PMC: 11550211. DOI: 10.1016/j.mtbio.2024.101312.

Clinical and preclinical studies of mesenchymal stem cells to alleviate peritoneal fibrosis.

Zheng L, Chen W, Yao K, Xie Y, Liao C, Zhou T Stem Cell Res Ther. 2024; 15(1):237.

PMID: 39080683 PMC: 11290310. DOI: 10.1186/s13287-024-03849-3.

Coupling Osmotic Efficacy with Biocompatibility in Peritoneal Dialysis: A Stiff Challenge.

Bonomini M, Masola V, Monaco M, Sirolli V, Di Liberato L, Prosdocimi T Int J Mol Sci. 2024; 25(6).

PMID: 38542505 PMC: 10971259. DOI: 10.3390/ijms25063532.

References

Noh H, Yu M, Kim H, Jeon J, Kwon S, Jin S . Uremia induces functional incompetence of bone marrow-derived stromal cells. Nephrol Dial Transplant. 2011; 27(1):218-25. DOI: 10.1093/ndt/gfr267. View

Mohyeddin Bonab M, Mohajeri M, Sahraian M, Yazdanifar M, Aghsaie A, Farazmand A . Evaluation of cytokines in multiple sclerosis patients treated with mesenchymal stem cells. Arch Med Res. 2013; 44(4):266-72. DOI: 10.1016/j.arcmed.2013.03.007. View

Najafi I, Alatab S, Atabak S, Majelan N, Sanadgol H, Makhdoomi K . Seventeen years' experience of peritoneal dialysis in Iran: first official report of the Iranian peritoneal dialysis registry. Perit Dial Int. 2013; 34(6):636-42. PMC: 4164408. DOI: 10.3747/pdi.2012.00054. View

Wang N, Li Q, Zhang L, Lin H, Hu J, Li D . Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6. PLoS One. 2012; 7(8):e43768. PMC: 3422344. DOI: 10.1371/journal.pone.0043768. View

Krediet R, Coester A, Parikova A, Smit W, Struijk D . New insights into the physiology of peritoneal fluid transport. Perit Dial Int. 2008; 28 Suppl 3:S144-9. View

Termorshuizen F, Korevaar J, Dekker F, van Manen J, Boeschoten E, Krediet R . Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol. 2003; 14(11):2851-60. DOI: 10.1097/01.asn.0000091585.45723.9e. View

Wei X, Yang X, Han Z, Qu F, Shao L, Shi Y . Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013; 34(6):747-54. PMC: 4002895. DOI: 10.1038/aps.2013.50. View

Roemeling-van Rhijn M, Reinders M, de Klein A, Douben H, Korevaar S, Mensah F . Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. Kidney Int. 2012; 82(7):748-58. DOI: 10.1038/ki.2012.187. View

Zhou Q, Bajo M, Peso G, Yu X, Selgas R . Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int. 2016; 90(3):515-24. DOI: 10.1016/j.kint.2016.03.040. View

10.

Moghadasali R, Mutsaers H, Azarnia M, Aghdami N, Baharvand H, Torensma R . Mesenchymal stem cell-conditioned medium accelerates regeneration of human renal proximal tubule epithelial cells after gentamicin toxicity. Exp Toxicol Pathol. 2012; 65(5):595-600. DOI: 10.1016/j.etp.2012.06.002. View

11.

Aroeira L, Aguilera A, Selgas R, Ramirez-Huesca M, Perez-Lozano M, Cirugeda A . Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis. 2005; 46(5):938-48. DOI: 10.1053/j.ajkd.2005.08.011. View

12.

De Miguel M, Fuentes-Julian S, Blazquez-Martinez A, Pascual C, Aller M, Arias J . Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012; 12(5):574-91. DOI: 10.2174/156652412800619950. View

13.

Uccelli A, Moretta L, Pistoia V . Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2009; 8(9):726-36. DOI: 10.1038/nri2395. View

14.

Ueno T, Nakashima A, Doi S, Kawamoto T, Honda K, Yokoyama Y . Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1 signaling. Kidney Int. 2013; 84(2):297-307. PMC: 3731556. DOI: 10.1038/ki.2013.81. View

15.

Makhlough A, Shekarchian S, Moghadasali R, Einollahi B, Hosseini S, Jaroughi N . Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients. Stem Cell Res Ther. 2017; 8(1):116. PMC: 5442691. DOI: 10.1186/s13287-017-0557-7. View

16.

Brimble K, Walker M, Margetts P, Kundhal K, Rabbat C . Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol. 2006; 17(9):2591-8. DOI: 10.1681/ASN.2006030194. View

17.

Alatab S, Najafi I, Atlasi R, Pourmand G, Tabatabaei-Malazy O, Ahmadbeigi N . A systematic review of preclinical studies on therapeutic potential of stem cells or stem cells products in peritoneal fibrosis. Minerva Urol Nefrol. 2017; 70(2):162-178. DOI: 10.23736/S0393-2249.17.02882-X. View

18.

De Becker A, Van Riet I . Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?. World J Stem Cells. 2016; 8(3):73-87. PMC: 4807311. DOI: 10.4252/wjsc.v8.i3.73. View

19.

Jain A, Blake P, Cordy P, Garg A . Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012; 23(3):533-44. PMC: 3294313. DOI: 10.1681/ASN.2011060607. View

20.

Moghadasali R, Azarnia M, Hajinasrollah M, Arghani H, Nassiri S, Molazem M . Intra-renal arterial injection of autologous bone marrow mesenchymal stromal cells ameliorates cisplatin-induced acute kidney injury in a rhesus Macaque mulatta monkey model. Cytotherapy. 2014; 16(6):734-49. DOI: 10.1016/j.jcyt.2014.01.004. View